Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says. Watch here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSinclair Pharma Regulatory News (SPH)

  • There is currently no data for SPH

Form 8 (OPD) - Sinclair IS Pharma plc

2 Dec 2014 09:50

RNS Number : 5941Y
Sinclair IS Pharma PLC
02 December 2014
 



FORM 8 (OPD)

 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the party to the offer making the disclosure:

Sinclair IS Pharma plc

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each party to the offer

Sinclair IS Pharma plc

(d) Is the party to the offer making the disclosure the offeror or the offeree?

Offeree

(e) Date position held:

1 December 2014

(f) Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

No

 

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

ordinary shares of 1 pence each

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

N/A

N/A

(2) Derivatives (other than options):

N/A

N/A

(3) Options and agreements to purchase/sell:

N/A

N/A

 

TOTAL:

N/A

N/A

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

N/A

Details, including nature of the rights concerned and relevant percentages:

N/A

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(c) Irrevocable commitments and letters of intent

 

Details of any irrevocable commitments or letters of intent procured by the party to the offer making the disclosure or any person acting in concert with it (see Note 3 on Rule 2.11 of the Code):

 

N/A

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe of any person acting in concert with the party to the offer making the disclosure:

 

Name

 

Number of Sinclair shares

 

% of issued share capital

Chris Spooner

8,989,164

1.8

Jean-Charles Tschudin

3,000,117

0.6

Grahame Cook

700,000

0.2

Christophe Foucher

191,200

0.04

 

Rights to subscribe

The number of awards of performance units of the Directors under the Company's value creation plan (VCP) are as follows. The awards may convert into nil-cost options over shares provided certain performance conditions are met.

 

Name

Options outstanding

Exercise price (p)

Exercisable date

Expiry date

Chris Spooner

3,600 VCP units

N/A

N/A

17 July 2019

Christophe Foucher

2,250 VCP units

N/A

N/A

17 July 2019

 

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3 for each additional class of relevant security.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

No

Supplemental Form 8 (SBL)

No

 

 

Date of disclosure:

2 December 2014

Contact name:

Alan Olby, CFO

Telephone number:

020 7467 6920

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEEKLLBBZLFZFBV
Date   Source Headline
12th Jul 20185:06 pmRNSForm 8.3 Sinclair Pharma plc Replacement
12th Jul 20185:05 pmRNSForm 8.3 Sinclair Pharma plc Replacement
12th Jul 201812:17 pmRNSForm 8.3 - Sinclair Pharma plc
12th Jul 201812:17 pmRNSForm 8.3 - Sinclair Pharma PLC
12th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
11th Jul 20182:20 pmRNSForm 8.3 - Sinclair Pharma Plc
11th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
11th Jul 20189:11 amRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc - Restated
11th Jul 20188:19 amRNSForm 8.5 (EPT/RI) - Sinclar Pharma Plc
10th Jul 20183:01 pmRNSForm 8.3 - Sinclair Pharma plc
10th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
10th Jul 201810:32 amRNSForm 8.5 (EPT/RI) - Sinclar Pharma Plc
9th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
6th Jul 20183:42 pmBUSForm 8.3 - SINCLAIR PHARMA PLC
6th Jul 20183:37 pmRNSForm 8.3 - Sinclair Pharma plc
6th Jul 20182:15 pmRNSForm 8.3 - [Sinclair Pharma plc]
6th Jul 201812:00 pmRNSForm 8.5 (EPT/RI) Sinclair Pharma Plc
6th Jul 201810:30 amRNSForm 8.3 - Sinclair Pharma Plc
5th Jul 20186:03 pmRNSStatement re Possible Offer
5th Jul 20181:32 pmRNSStatement re Possible Offer
5th Jul 20187:00 amRNSTrading Update
13th Jun 201811:06 amRNSResult of AGM
13th Jun 20187:00 amRNSAGM Statement
23rd May 20188:00 amRNSSilhouette Instalift wins NewBeauty Magazine Award
18th May 20188:00 amRNSPublication of Annual Report and Accounts
30th Apr 20187:01 amRNSFinal Results
30th Apr 20187:00 amRNSSinclair secures Euro23 million debt facility
26th Mar 20187:00 amRNSUpdate on US distribution of Silhouette Instalift
6th Mar 20187:00 amRNSHolding(s) in Company
2nd Mar 20187:00 amRNSHolding(s) in Company
1st Mar 201810:06 amRNSHolding(s) in Company
22nd Feb 20187:01 amRNSSinclair announces $5m investment by EW Healthcare
22nd Feb 20187:00 amRNSSinclair and ThermiGen terminate agreement
17th Jan 20187:00 amRNSDirector/PDMR Shareholding
16th Jan 20182:15 pmRNSDirector/PDMR Shareholding
16th Jan 20187:00 amRNSEllansé® Approved for Sale in Brazil
15th Jan 20187:00 amRNSTrading Statement
19th Oct 20172:25 pmRNSNew CE mark granted for Silhouette Soft
2nd Oct 20177:15 amRNSHardman Research: Demand growing in target markets
19th Sep 20177:00 amRNSInterim Results
12th Jul 20177:47 amRNSHolding(s) in Company
12th Jul 20177:15 amRNSHardman Research: Promising start in the US
11th Jul 20177:00 amRNSTrading Update for the 6 months to 30 June 2017
5th Jul 20177:00 amRNSHolding(s) in Company
19th Jun 20177:00 amRNSAcquisition
14th Jun 20177:00 amRNSHolding(s) in Company
24th May 20177:00 amRNSHolding(s) in Company
26th Apr 201710:50 amRNSResult of AGM
30th Mar 20174:55 pmRNSAnnual Financial Report
30th Mar 20177:00 amRNSAdditional listing

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.